|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HIST1H2BH |
Gene summary for HIST1H2BH |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HIST1H2BH | Gene ID | 8345 |
| Gene name | H2B clustered histone 9 | |
| Gene Alias | H2B/j | |
| Cytomap | 6p22.2 | |
| Gene Type | protein-coding | GO ID | GO:0006323 | UniProtAcc | Q93079 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8345 | HIST1H2BH | LZE4T | Human | Esophagus | ESCC | 4.86e-06 | 3.56e-01 | 0.0811 |
| 8345 | HIST1H2BH | LZE22T | Human | Esophagus | ESCC | 7.27e-03 | 4.50e-01 | 0.068 |
| 8345 | HIST1H2BH | LZE24T | Human | Esophagus | ESCC | 7.34e-06 | 2.44e-01 | 0.0596 |
| 8345 | HIST1H2BH | LZE21T | Human | Esophagus | ESCC | 7.59e-03 | 4.54e-01 | 0.0655 |
| 8345 | HIST1H2BH | P1T-E | Human | Esophagus | ESCC | 1.35e-17 | 9.85e-01 | 0.0875 |
| 8345 | HIST1H2BH | P2T-E | Human | Esophagus | ESCC | 2.02e-06 | 1.91e-01 | 0.1177 |
| 8345 | HIST1H2BH | P4T-E | Human | Esophagus | ESCC | 7.69e-14 | 4.22e-01 | 0.1323 |
| 8345 | HIST1H2BH | P5T-E | Human | Esophagus | ESCC | 7.55e-03 | 1.40e-01 | 0.1327 |
| 8345 | HIST1H2BH | P10T-E | Human | Esophagus | ESCC | 3.25e-23 | 5.66e-01 | 0.116 |
| 8345 | HIST1H2BH | P11T-E | Human | Esophagus | ESCC | 3.43e-03 | 2.22e-01 | 0.1426 |
| 8345 | HIST1H2BH | P12T-E | Human | Esophagus | ESCC | 2.31e-11 | 3.18e-01 | 0.1122 |
| 8345 | HIST1H2BH | P15T-E | Human | Esophagus | ESCC | 1.34e-11 | 3.75e-01 | 0.1149 |
| 8345 | HIST1H2BH | P16T-E | Human | Esophagus | ESCC | 3.75e-03 | 2.02e-01 | 0.1153 |
| 8345 | HIST1H2BH | P20T-E | Human | Esophagus | ESCC | 3.19e-12 | 4.38e-01 | 0.1124 |
| 8345 | HIST1H2BH | P21T-E | Human | Esophagus | ESCC | 8.21e-03 | 2.29e-01 | 0.1617 |
| 8345 | HIST1H2BH | P22T-E | Human | Esophagus | ESCC | 9.35e-18 | 3.85e-01 | 0.1236 |
| 8345 | HIST1H2BH | P26T-E | Human | Esophagus | ESCC | 5.82e-20 | 4.76e-01 | 0.1276 |
| 8345 | HIST1H2BH | P27T-E | Human | Esophagus | ESCC | 8.86e-08 | 3.06e-01 | 0.1055 |
| 8345 | HIST1H2BH | P30T-E | Human | Esophagus | ESCC | 3.94e-03 | 3.40e-01 | 0.137 |
| 8345 | HIST1H2BH | P31T-E | Human | Esophagus | ESCC | 2.41e-11 | 3.95e-01 | 0.1251 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HIST1H2BH | SNV | Missense_Mutation | c.205G>A | p.Asp69Asn | p.D69N | Q93079 | protein_coding | deleterious_low_confidence(0.05) | benign(0.251) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response | |
| HIST1H2BH | SNV | Missense_Mutation | c.229G>A | p.Glu77Lys | p.E77K | Q93079 | protein_coding | deleterious_low_confidence(0.04) | possibly_damaging(0.812) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| HIST1H2BH | SNV | Missense_Mutation | c.229N>C | p.Glu77Gln | p.E77Q | Q93079 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.975) | TCGA-AC-A6IW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| HIST1H2BH | SNV | Missense_Mutation | c.340N>C | p.Glu114Gln | p.E114Q | Q93079 | protein_coding | deleterious_low_confidence(0.02) | benign(0.155) | TCGA-DG-A2KK-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| HIST1H2BH | SNV | Missense_Mutation | c.69N>C | p.Gln23His | p.Q23H | Q93079 | protein_coding | deleterious_low_confidence(0.01) | benign(0.012) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| HIST1H2BH | SNV | Missense_Mutation | c.331N>A | p.Ala111Thr | p.A111T | Q93079 | protein_coding | tolerated_low_confidence(0.06) | benign(0.079) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| HIST1H2BH | SNV | Missense_Mutation | c.340N>A | p.Glu114Lys | p.E114K | Q93079 | protein_coding | tolerated_low_confidence(0.07) | benign(0.034) | TCGA-AG-4001-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| HIST1H2BH | SNV | Missense_Mutation | rs759587313 | c.88N>T | p.Arg30Cys | p.R30C | Q93079 | protein_coding | tolerated_low_confidence(0.09) | benign(0.082) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| HIST1H2BH | SNV | Missense_Mutation | novel | c.217N>T | p.Arg73Cys | p.R73C | Q93079 | protein_coding | tolerated_low_confidence(0.11) | benign(0.041) | TCGA-EO-A22T-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| HIST1H2BH | SNV | Missense_Mutation | c.205G>C | p.Asp69His | p.D69H | Q93079 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.597) | TCGA-05-4410-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |